Clinical effect of danazol in patients with IgA nephropathy.
A multi-center study on the clinical effect of danazol in patients with IgA nephropathy is described. Two different doses of oral administration, including 200 mg or 300 mg per day, were employed in the present study. Urinalysis and measurements of complement components, i.e. C3 and C4, were performed before, and in the eighth and 20th week after the administration of danazol. It was demonstrated that 200 or 300 mg of danazol administration was effective in reducing the amount of proteinuria and in increasing the levels of serum complement components in the patients. It is concluded that the administration of danazol may be useful for treatment of patients with IgA nephropathy.
Tomino
Y
Y
Sakai
H
H
Hanzawa
S
S
Ohno
J
J
Kitajima
T
T
Sakai
O
O
D000284:Administration, Oral; D000328:Adult; D002986:Clinical Trials as Topic; D003176:Complement C3 / Q000032:analysis; D003181:Complement C4 / Q000032:analysis; D003613:Danazol / Q000008:administration & dosage / Q000494:pharmacology* / Q000627:therapeutic use; D004176:Dipyridamole / Q000008:administration & dosage / Q000627:therapeutic use; D005922:Glomerulonephritis, IGA / Q000097:blood / Q000188:drug therapy*; D006417:Hematuria / Q000188:drug therapy; D006801:Humans; D007564:Japan; D008297:Male; D011245:Pregnadienes / Q000494:pharmacology*; D011507:Proteinuria / Q000188:drug therapy
D003176:Complement C3; D003181:Complement C4; D011245:Pregnadienes; D004176:Dipyridamole; D003613:Danazol